Breakthrough Cancer Therapy DTC: Boldly Emphasizing the Positive
This article explores the trend in direct-to-consumer (DTC) ads for 'breakthrough' cancer therapies.
Wearables, Ingestibles, Implantables: The Inescapable Future of Healthcare
This article discusses the intrusiveness of wearables et al and other issues of these technologies as they relate to healthcare outcomes and communications arena and whether pharma marketers should get on the bandwagon.
Pharma Marketing News Vol. 14, No. 5: June 2015
Welcome to Vol. 14, Issue No. 5 (JUNE 2015) of Pharma Marketing News. Creativity and new technology in the service of patient communications and healthcare outcomes are the themes of this issue.
Medical Science Liaison Roles: Enigma and Dilemma
After many hundreds of millions of penalty dollars from questionable sales and marketing practices, are pharmaceutical companies finally doing the 'right. thing, at least where MSL roles are concerned?
How to Achieve Digital Pharma Marketing Results: Dealing with Disruption
This article focuses on digital disruption, which is the focus of a chapter in the book RESULTS: The Future of Pharmaceutical and Healthcare Marketing written by by R.J. Lewis (aka RJ) et al.
PinUp: AZ Plans More Medical TweetChats, Are News Media Anti-Pharma? Another Diclegis Celebrity Post,...
Welcome to the July 5, 2016, issue of Pharma Industry News Update (aka PinUp). PinUp is published every Tuesday and Friday as part of your Pharma Marketing News subscription service. It features curated pharma industry news and views of topical interest from a variety of sources.
Pharma on Instagram: How Top Drug Companies Use It Today & May Use It...
Instagram may become the social medium of choice for pharma marketers now that it has been purchased by Face-book and has added several new features that allow marketers to potentially thwart FDA regulations.
OpEd: Drug Importation Crisis: Terror Politics to the Rescue!
The FDA just played the terrorist trump card in its battle against the legalization of the reimportation of drugs.
Ramifications of FDA Regulatory Actions: Helping FDA Find a New Media Regulatory Pathway
Arnold Friede, counsel to the law firm McDermott Will & Emery LLP, and former Senior Counsel at Pfizer, believes that there is an opportunity now to make a strong and compelling argument for the adoption of rational regulatory policies by the FDA that address the unique features not only of sponsored links, but of other kinds of new communication tools, such as social media.
Limiting Bias in Commercially Supported CME
Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.
